Japan's Price Cuts Slated For April Bring Old, New Blues For Industry
Xolair, Lixiana, Keytruda Hard Hit
Next month’s regular reimbursement price cut in Japan includes some large reductions for big-selling drugs, while one new rule has been applied for the first time.
You may also be interested in...
Japan Pricing Environment ‘Highly Unpredictable’: PhRMA
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.
EFPIA Wants Continued And More Inclusive Japan Policy Dialog
The European research-based pharma industry in Japan continues to call for a pricing system that better encourages innovation and for inclusive discussions on reforms that address health system challenges and focus on patients.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.